Irbesartan
CAS NO.:138402-11-6
MF:C25H28N6O
EINECS NO.:604-078-2
MF:C25H28N6O
EINECS NO.:604-078-2
API015
Quantity
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.
It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy.
Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes,
elevated serum creatinine,
and proteinuria.A combination product with hydrochlorothiazide is indicated for hypertension
in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
